- Home
- CR vs ROIV Comparison
CR vs ROIV Comparison
Compare CR & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CR
- ROIV
- Stock Information
- Founded
- CR 1855
- ROIV 2014
- Country
- CR United States
- ROIV United Kingdom
- Employees
- CR N/A
- ROIV N/A
- Industry
- CR Metal Fabrications
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- CR Industrials
- ROIV Health Care
- Exchange
- CR Nasdaq
- ROIV Nasdaq
- Market Cap
- CR 8.9B
- ROIV 7.8B
- IPO Year
- CR N/A
- ROIV N/A
- Fundamental
- Price
- CR $188.01
- ROIV $11.28
- Analyst Decision
- CR Strong Buy
- ROIV Buy
- Analyst Count
- CR 4
- ROIV 4
- Target Price
- CR $197.75
- ROIV $17.50
- AVG Volume (30 Days)
- CR 368.5K
- ROIV 6.6M
- Earning Date
- CR 07-28-2025
- ROIV 08-07-2025
- Dividend Yield
- CR 0.49%
- ROIV N/A
- EPS Growth
- CR 54.50
- ROIV N/A
- EPS
- CR 5.76
- ROIV N/A
- Revenue
- CR $2,178,600,000.00
- ROIV $29,053,000.00
- Revenue This Year
- CR $10.22
- ROIV $2.64
- Revenue Next Year
- CR $11.07
- ROIV $378.09
- P/E Ratio
- CR $32.89
- ROIV N/A
- Revenue Growth
- CR 17.22
- ROIV N/A
- 52 Week Low
- CR $127.04
- ROIV $8.73
- 52 Week High
- CR $191.00
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- CR 67.86
- ROIV 53.61
- Support Level
- CR $176.06
- ROIV $11.25
- Resistance Level
- CR $185.81
- ROIV $11.82
- Average True Range (ATR)
- CR 3.97
- ROIV 0.33
- MACD
- CR -0.09
- ROIV -0.00
- Stochastic Oscillator
- CR 79.07
- ROIV 52.97
About CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and electronics, and process flow technologies. Crane generated approximately $2.1 billion in revenue in 2024.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.